US-based biotechnology company Trovagene has chosen global contract research organisation (CRO) PRA Health Sciences to carry out its Phase lb/ll clinical trial of PCM-075, a polo-like kinase 1 (PLK1) inhibitor, to treat patients with acute myeloid leukaemia (AML).

As part of the latest arrangement, PRA will help Trovagene in clinical site recruitment, clinical operations and regulatory proceedings for the development of PCM-075 in AML.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Trovagene has already filed an investigational new drug (IND) application and protocol for PCM-075 to the Food and Drug Administration (FDA).

Once approved, the company is planning to commence the Phase lb/ll study that will assess the safety, tolerability, dosage and scheduling, as well as preliminary efficacy of PCM-075 in patients with AML.

"We look forward to generating clinical data that we believe will assess the safety, tolerability, and anti-leukaemic activity of PCM-075 in a haematological malignancy."

Trovagene CEO Bill Welch said: “We look forward to generating clinical data that we believe will assess the safety, tolerability, and anti-leukaemic activity of PCM-075 in a haematological malignancy.”

The company’s PCM-075 is an adenosine triphosphate (ATP) competitive inhibitor of the serine / threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in several different hematologic malignancies, as well as solid tumours such as breast, prostate, ovarian, lung, gastric and colon cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The PLK1is orally bioavailable and has already been explored in an initial, open-label, dose-escalation safety Phase l study in patients with advanced metastatic solid tumour cancers.

PCM-075 demonstrated an acceptable safety profile, as well as anti-tumour activity in the study.

Last month, Trovagene signed a supplier agreement with Italy’s Nerviano Medical Sciences subsidiary NerPharMato manufacture drug product for PCM-075.